Fortress Biotech Inc (FBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.72+0.37%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · FBIO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 68.5 | 63.3 | 57.7 | 84.5 | 75.7 | 68.8 | 45.6 | 36.6 | 26.9 | 17.2 | 16.5 | 0.9 | — | — | — | — |
| Total Revenues | 68.5 | 63.3 | 57.7 | 84.5 | 75.7 | 68.8 | 45.6 | 36.6 | 26.9 | 17.2 | 16.5 | 0.9 | — | — | — | — |
| Cost of Revenues | 23.6 | 20.9 | 20.9 | 22.9 | 30.8 | 32.1 | 14.6 | 10.5 | 6.1 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 68.7 | 96.4 | 87.7 | 91.0 | 113.7 | 86.8 | 61.2 | 55.6 | — | — | — | — | — | — | — | — |
| R&D Expenses | — | — | — | 106.1 | 134.9 | 128.9 | 64.1 | 81.3 | 87.4 | 48.3 | 35.1 | 29.8 | 10.2 | 25.7 | 17.5 | 8.6 |
| Operating Income | (29.2) | (70.2) | (110.4) | (142.3) | (203.6) | (188.5) | (94.3) | (110.8) | (120.0) | (89.8) | (65.7) | (50.5) | (20.7) | (35.8) | (27.2) | (35.0) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | 5.9 | 3.7 | 1.5 | 1.3 | 1.9 | 0.7 | 0.1 |
| Interest & Investment Income | 3.5 | 2.5 | 2.7 | 3.0 | 1.4 | 0.6 | 1.5 | 2.6 | 1.1 | 0.8 | 0.3 | 0.2 | 0.7 | 0.5 | 0.2 | 0.2 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | 5.0 | 3.4 | 1.2 | 0.7 | 1.4 | 0.4 | (0.1) |
| Other Non-Operating Income / Expenses | 175.2 | 36.7 | (10.2) | (11.3) | (9.9) | 24.2 | (8.6) | 9.2 | (10.8) | (7.7) | (5.6) | (3.4) | — | — | — | — |
| Asset Writedown | — | — | 3.7 | 3.1 | — | 0.0 | 0.0 | — | — | — | 0.0 | 0.0 | 0.7 | — | — | — |
| EBT, Incl. Unusual Items | 146.0 | (33.5) | (120.5) | (153.6) | (213.5) | (164.4) | (102.8) | (101.7) | (130.8) | (97.5) | — | — | — | — | — | — |
| Income Tax Expense | 4.8 | (0.6) | 0.3 | 0.5 | 0.4 | 0.5 | 0.5 | 0.0 | 0.0 | 1.5 | — | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Minority Interest | 29.4 | (39.7) | (74.9) | (93.5) | (127.3) | (100.1) | (56.5) | (61.7) | (57.8) | (33.0) | (16.2) | (5.5) | — | — | — | — |
| Net Income | 142.0 | 6.8 | (46.0) | 31.0 | (86.6) | (64.7) | (46.5) | (40.0) | (84.1) | (66.9) | (55.1) | (48.4) | (20.4) | (37.2) | (27.6) | (36.4) |
| Per Share | ||||||||||||||||
| Basic EPS | 4.47 | (0.07) | (2.69) | (8.47) | (15.97) | (0.79) | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | 4.47 | (0.07) | (2.69) | (8.47) | (15.97) | (0.79) | — | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 2.15 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 31.8 | 27.9 | 20.8 | 8.1 | 5.9 | 81.7 | — | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 31.8 | 27.9 | 20.8 | 8.1 | 5.9 | 81.7 | — | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | — | (88.6) | (64.8) | (50.5) | — | — | — | — |
| EBIT | (29.2) | (70.2) | (110.4) | (142.3) | (203.6) | (188.5) | (94.3) | (110.8) | (120.0) | (89.8) | (65.7) | (50.5) | (20.7) | (35.8) | (27.2) | (35.0) |
| Effective Tax Rate | 3.3% | — | — | -0.3% | -0.2% | -0.3% | -0.5% | 0.0% | 0.0% | -1.6% | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.